Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Adrian Serone"'
Autor:
Xavier Roblin, Adrian Serone, Oh Kyu Yoon, Luting Zhuo, Ethan Grant, Geert R. D'Haens, Rene Galien, Jacky Woo, Jinfeng Liu
Publikováno v:
Inflammatory bowel diseases, 28(8), 1207-1218. John Wiley and Sons Inc.
Background Pro-inflammatory cytokines are dysregulated in Crohn’s disease (CD) and could serve as surrogate markers to improve diagnostic and therapeutic approaches, potentially addressing an unmet need. We profiled circulating biomarkers and whole
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9667d994057ee65650c4371d28dc584d
https://pure.amc.nl/en/publications/effects-of-jak1preferential-inhibitor-filgotinib-on-circulating-biomarkers-and-whole-blood-genespathways-of-patients-with-moderately-to-severely-active-crohns-disease(d85f086f-a574-4321-906c-58827389c799).html
https://pure.amc.nl/en/publications/effects-of-jak1preferential-inhibitor-filgotinib-on-circulating-biomarkers-and-whole-blood-genespathways-of-patients-with-moderately-to-severely-active-crohns-disease(d85f086f-a574-4321-906c-58827389c799).html
Autor:
Walter Reinisch, Adrian Serone, Xavier Hébuterne, Tanja Kühbacher, Maria Kłopocka, Xavier Roblin, Jens Brodbeck, Kim Etchevers, René Galien, Ethan Grant, Chantal Tasset, Oh Kyu Yoon, Shiva Zaboli, Séverine Vermeire
Publikováno v:
Tissue Barriers. 11
The validity and relevance of histologic disease activity in Crohn's disease (CD) is unclear, owing to disconnects with endoscopic pathology. Here, we explore relationships between endoscopic, histologic, and molecular activity. This post hoc analysi
Autor:
Jason Goh, Xavier Roblin, Oh Kyu Yoon, Rene Galien, Geert R. D'Haens, Jacky Woo, Ethan Grant, Adrian Serone, James Lui, Luting Zhuo
Publikováno v:
Posters.
Autor:
Oh Kyu Yoon, Adrian Serone, Robert Petryka, Chantal Tasset, Severine Vermeire, Xavier Roblin, Jason Goh, Shiva Zaboli, Xavier Hébuterne, Maria Kłopocka, Jens Brodbeck, Ethan Grant, Rene Galien, Walter Reinisch
Publikováno v:
Posters.
Introduction Filgotinib (FIL) is a JAK1 inhibitor under phase 3 clinical evaluation for treatment of IBD. We conducted a post hoc analysis in patients (pts) with moderately to severely active Crohn’s disease (CD) to assess the effect of FIL on mark
Autor:
R Galien, Jacky Woo, L Zhuo, Adrian Serone, Xavier Roblin, O K Yoon, J Liu, G R D’Haens, E Grant
Publikováno v:
Journal of Crohn's and Colitis. 14:S457-S458
Background A Phase 2 study of the JAK1-selective inhibitor filgotinib (FIL) dosed at 200 mg once daily for 10 weeks in moderately to severely active CD (FITZROY, ClinicalTrial.gov #NCT02048618) demonstrated significantly higher clinical remission rat
Autor:
Shiva Zaboli, Severine Vermeire, Chantal Tasset, Walter Reinisch, Rene Galien, Maria Kłopocka, Xavier Hébuterne, Ethan Grant, Adrian Serone, Oh Kyu Yoon, Robert Petryka, Jens Brodbeck, Xavier Roblin
Publikováno v:
Gastroenterology. 158:S-1200
Autor:
Rene Galien, James Liu, Luting Zhuo, Ethan Grant, Xavier Roblin, Geert R. D'Haens, Adrian Serone, Jacky Woo, Oh Kyu Yoon
Publikováno v:
Gastroenterology. 158:S-1201
Autor:
Adrian Serone, Robert Petryka, Walter Reinisch, Shiva Zaboli, O K Yoon, Jens Brodbeck, Chantal Tasset, Xavier Hébuterne, Maria Kłopocka, Rene Galien, Xavier Roblin, Severine Vermeire, E Grant
Publikováno v:
Journal of Crohn's and Colitis. 14:S381-S381
Background Filgotinib (FIL) is a JAK1 inhibitor under phase 3 clinical evaluation for treatment of IBD. We conducted a post hoc analysis in a subset of patients with moderately to severely active CD from FITZROY (NCT02048618) to assess the effect of
Autor:
Severine Vermeire, Xavier Roblin, Chantal Tasset, A Van der Aa, R Galien, A. M. Mirza, Jacky Woo, W Li, Adrian Serone, L Goyal, G. D'Haens, Satish Keshav
Publikováno v:
IBD.
Introduction Filgotinib (FIL) is a JAK1-selective inhibitor currently in Phase III development for the treatment of ulcerative colitis and Crohn’s disease (CD). In a Phase II study in patients with moderately to severely active CD (FITZROY, Clinica
Autor:
Gert De Hertogh, Chantal Tasset, Kim Etchevers K, Severine Vermeire, Brian G. Feagan, Geert R. D'Haens, Adrian Serone, W. Reinisch, Chohee Yun, William J. Sandborn, Annegret Van der Aa
Publikováno v:
Inflammatory Bowel Diseases. 24:S16-S17